Medtronic plc (MDT) scored on five pillars from its reported financial statements, and ranked against 212 Healthcare companies.
Medtronic plc (MDT) scores 6.0 out of 10 as of , computed from its reported financial statements. That reads as solid quality. The reading rests on efficiency, and growth is what holds it back.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
We cannot judge Medtronic plc yet, because fewer than five years had both a return on capital and a cost of capital we could measure. This is not a “no”.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
As of October 19, 2026, Medtronic plc scores 6.0 out of 10 on the Lemma Quality Score, a reading of solid quality. This band covers companies that do several things well but not everything, so the pillar detail below matters more than the headline. Nothing in it comes from the share price or from forecasts: it is Medtronic plc’s own reported numbers, scored pillar by pillar.
Among the 212 Healthcare companies with a published score, that ranks at the 74th percentile, in the better half of its peers. The median across the group is 4.4, and the top quarter begins at 6.0, so Medtronic plc is well above the typical company here.
Medtronic plc’s profitability score is 4.9 out of 10 (average). Against a median of 2.7 among 210 Healthcare companies, that is well above the group and the 71st percentile. An average profitability reading usually means the company earns a fair return without obvious pricing power, so the other pillars decide more of the story.
On solvency, Medtronic plc scores 6.9, an average reading. Its peers have a median of 6.5 across 150 Healthcare companies, which places it in line with them, at the 55th percentile. Leverage in the middle of the range is rarely a problem in good years, and it is worth watching how quickly it would tighten in a weak one.
Medtronic plc’s growth score is 3.4 out of 10 (weak). Against a median of 4.9 among 107 Healthcare companies, that is well below the group and the 34th percentile. When growth is this low the question is whether it is a pause or a trend, and the history behind the filings is the place to look.
Efficiency scores 7.7 out of 10, which reads as strong. The median across 200 Healthcare companies is 6.0, so Medtronic plc is well above its peers on this pillar and ranks at the 74th percentile. Efficiency at this level means the company needs comparatively little capital to produce what it sells.
Predictability scores 7.5 out of 10, which reads as strong. The median across 207 Healthcare companies is 3.4, so Medtronic plc is well above its peers on this pillar and ranks at the 92nd percentile. Steady results like these are what make a long term view of the business easier to hold.
The gap between Medtronic plc’s best and worst pillar is wide: efficiency at 7.7 against growth at 3.4, 4.3 points apart. An average of two readings this different deserves a closer look than the headline number. Leading with efficiency points to disciplined use of capital, a strength that compounds quietly. Slow growth limits how fast the business can compound, even when everything else is in order.
Of everything that could lift Medtronic plc’s score, growth matters most. Bringing it up to the 4.9 median of Healthcare companies would take the overall from 6.0 to roughly 6.3. The weights add up to 100 points (profitability 25, solvency 20, growth 20, efficiency 15, predictability 20), and Medtronic plc has a reading on every pillar.
For a fair comparison, start with companies of a similar size: the Healthcare companies below are nearest to Medtronic plc by market value, each scored on the same pillars.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Medtronic plc scores 6.0 out of 10, which reads as solid quality. Its strongest pillar is efficiency, its weakest is growth. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Medtronic plc ranks at the 74th percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against Medtronic plc’s 6.0.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for MDT are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card